Study to evaluate potential COVID-19 treatment regimen in hospitalized patients
The National Institute of Allergy and Infectious Diseases has launched a clinical trial to evaluate a potential COVID-19 treatment regimen for hospitalized patients that combines remdesivir with interferon beta-1a, a medication approved to treat multiple sclerosis that laboratory studies suggest may benefit patients with COVID-19.
The trial expects to enroll more than 1,000 hospitalized adults with COVID-19 in the United States and abroad who have abnormal chest X-rays or need supplemental oxygen or mechanical ventilation. Preliminary results are expected this fall.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…